logo
Plus   Neg
Share
Email

Pfizer Reports FDA Approval For Expanded Indication Of EUCRISA - Quick Facts

Pfizer Inc. (PFE) announced the U.S. FDA has approved the company's supplemental New Drug Application for EUCRISA ointment, 2%, extending the lower age limit from 24 months down to 3 months in children with mild-to-moderate atopic dermatitis. The company said the supplemental approval makes EUCRISA the first and only steroid-free, topical prescription medication for mild-to-moderate atopic dermatitis patients as young as 3 months of age.

The FDA approval for the expanded indication of EUCRISA was supported by data from a Phase 4, open-label, clinical study.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Macy's is offering a sneak peek of its Black Friday deals for this year, so that shoppers can get a head start on finding some of the best deals. The department store has unveiled its Black Friday deals that will be available next month across categories, including fashion, fine jewelry, tech, beauty, toys and home specials. Some of the deals will be available for as low as $5. Italy's antitrust watchdog has opened an investigation against Google for an alleged abuse of dominant position in the Italian market for display advertising. This refers to the space publishers and website owners make available for the display of advertising content. Shares of Deutsche Bank AG were gaining around 3 percent in German trading after the banking major reported Wednesday a profit in its third quarter, compared to prior year's loss mainly driven by strong Investment Bank revenues. Looking ahead, the bank said it remains on track to meet all financial and strategic targets related to its transformation plan.
Follow RTT